Explore
Tyrosine Kinases as Druggable Targets in Cancer
Huan Ren (editor)
2019
0 Ungluers have
Faved this Work
Login to Fave
Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 12 times via unglue.it ebook links.
- 12 - pdf (CC BY) at mts.intechopen.com.
Keywords
- Clinical & internal medicine
- Diseases & disorders
- medicine
- oncology
Links
DOI: 10.5772/intechopen.79884Editions